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Abstract: Objectives: The objectives of the present study are to investigate the association among 
symptoms of depression and anxiety, sociodemographic variables and personality factors and also verify 
the predictive power of these variables in cancer outpatients. Method: The sample was composed by 220 
individuals, 138 (62.7%) women and 82 (37.3%) men. The instruments used were: Questionnaire on 
sociodemographic and clinical data; NEO-FFI Personality Inventory Revised (NEO-FFI-R) and Hospital 
Anxiety and Depression Scale (HADS). The t test and the Spearman correlation were used to verify 
the relation between sociodemographic and clinic variables and symptoms of anxiety and depression. A 
Multiple Linear Regression analysis was made to verify the predictive power of sociodemographic and 
clinic variables and personality factors. Results: The personality factor neuroticism was predictor of 
anxiety symptoms. The variable previous psychiatric history and the personality factors neuroticism and 
extraversion were predictors of depressive symptoms. Conclusion: Depression and anxiety symptoms 
are associated with some sociodemographic variables and personality factors, and these variables can 
be deemed risk factors for the development of these symptoms. It is important that health professionals 
who follow-up this population design strategies to collect this information, in order to help patients 
manage treatment the best way possible. 
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[es] Síntomas de depresión y ansiedad en pacientes con cáncer: varia-
bles predictivas
Resumen: Objetivos: Los objetivos del presente estudio son investigar la asociación entre síntomas 
de depresión y ansiedad, variables sociodemográficas y factores de personalidad y también verificar 
el poder predictivo de estas variables en pacientes con cáncer. Método: La muestra estuvo compuesta 
por 220 individuos, 138 (62,7%) mujeres y 82 (37,3%) hombres. Los instrumentos utilizados fueron: 
Cuestionario sobre datos sociodemográficos y clínicos; NEO-FFI Personality Inventory Revised (NEO-
FFI-R) and Hospital Anxiety and Depression Scale (HADS). La prueba t y la correlación de Spearman 
se usaron para verificar la relación entre las variables sociodemográficas y clínicas y los síntomas 
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de ansiedad y depresión. Se realizó un análisis de Regresión Linear Múltiple para verificar el poder 
predictivo de las variables sociodemográficas y clínicas y los factores de personalidad. Resultados: el 
factor de personalidad neuroticismo fue predictor de síntomas de ansiedad. La variable antecedentes 
psiquiátricos previos y los factores de personalidad neuroticismo y extraversión fueron predictores de 
síntomas depresivos. Conclusión: Los síntomas de depresión y ansiedad están asociados con algunas 
variables sociodemográficas y factores de personalidad, y estas variables pueden considerarse factores 
de riesgo para el desarrollo de estos síntomas. Es importante que los profesionales del campo de la salud 
que hacen el seguimiento de esta población proyecten estrategias para colectar esta información, a fin 
de ayudar a los pacientes a administrar el tratamiento de la mejor manera posible.
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1. Introduction
Individuals diagnosed with cancer and undergoing any kind of cancer treatment 
can suffer from distress, that causes a psychological effect in their life and in their 
relative’s life, making easier the emergence of depressive and anxiety symptoms(1,2). 
These patients, comparing with general population, present 3 to 5 times higher risk 
of developing depressive symptoms and disorders(3), and depressive cancer patients 
have higher mortality rates than those non-depressive(4).
According to some studies, 10% to 37% of cancer patients present depressive 
symptomatology(5-9).These symptoms can cause low motivation and complications 
during adherence treatment process. Beyond that, they can negatively affect quality 
of life and disease process, getting both prognostic and recovering worse and 
increasing death risk(6,10).
Anxiety symptoms are, likewise, found in most cancer patients and can be caused 
by many reasons, like extensive treatments, recurrent hospitalizations, appointment 
waiting time, among others(11). Anxiety prevalence in cancer patients can vary 
between 10% to 34%(5,8,12). 
In that way, it is possible to realize that symptoms of anxiety and depression are 
expected in this population, as a reaction to current condition or as an expression of cancer 
coping difficulties. On the other hand, it is understood that, beyond expected emotional 
reactions, there are some kinds of behaviors, as a response to different scenarios, 
that vary from one patient to another. These emotional and behavioral reactions can 
appear from individual personality factors that are important determinants of health 
behaviors(13). According to American Psychological Association (APA)(14), personality 
can be understood like a dynamic and complex integration of characteristics, shaped 
by wishes, values, self-concept, abilities and emotional patterns.
The concept of personality has many definitions. Besides this, there are also 
different theoretical models trying to explain it. One of these models is the Big 
Five(15). The Big Five theory advanced gradually, and it is currently considered one 
of the most up-to-date in the health sciences. Moreover, the validity of this theory in 
Brazilian samples has already been proven(16,17).
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Studies indicate that life experiences and personality factors are related to 
remaining of anxiety and depression symptoms. Life experiences classified as 
negative are linked to depression permanence and relapse(18) and to onset of anxiety 
disorders(19). Other previous researchers also found relation between personality 
factors and symptoms of depression(20) and anxiety(21-23).
At the end of this brief revision, it is possible to understand that different aspects 
can influence individual beliefs, reactions and behavior, also interfering in disease 
evolution and treatment, and, finally, in the outcomes measures. Acknowledging 
the association between these factors can improve the developing of psychological 
strategies able to modify behaviors associated with prognostic improvement and 
better health outcomes(11,24).
In this context, the objectives of the present study are: a) to evaluate the presence 
of depressive and anxiety symptoms in cancer outpatients; b) to investigate the 
association among symptoms of depression and anxiety and sociodemographic 
variables (sex, age, time since diagnosis, education level, previous psychiatric 
history, family psychiatric history and family cancer history) and also verify 
the predictive power of these variables; and c) to investigate the relation among 
symptoms of depression and anxiety and personality factors, and verify if these 
factors are predictors of symptomatologies in this population.
2. Method
2.1. Design
It is a quantitative, transversal and exploratory study.
2.2. Participants
The final sample was composed by 220 outpatients undergoing treatment to different 
oncology specialties. Based on Brazilian National Cancer Institute (Inca)(25) estimates 
to 2016-2017 biennium to Porto Alegre city – including rates of cancer incidence and 
new cases (approximately 9,044), a sample size was calculated to define participants 
number, using a 5% of sample error estimation and confidence level of 95%. 
The participants were selected by convenience, contacted and invited to participate 
on the study, in waiting room of the hospital where they were being treated, while 
waiting to medical appointment. In total, 347 patients were invited to participate in 
the survey, among them, 68 refused, 41 didn’t have cancer diagnostic and/or were at 
the hospital for first appointment, and 18 reported not having clinical conditions to 
collaborate with the study. 
2.3. Instruments
The following instruments were applied, complying the order below:
a) Questionnaire on sociodemographic and clinical data: instrument utilized to 
collect sociodemographic and cancer data of the sample;
b) NEO-FFI Personality Inventory Revised (NEO-FFI-R)(26,27): it is an inventory 
composed by affirmative questions, to which the individual answers using one 
of the likert scale five alternatives described. The five domains Neuroticism, 
Lima, M.P.; de Oliveira, D.S.; Irigaray, T.Q. Psicooncología 2018; 15(2): 373-384376
Extraversion, Openness to experience, Agreeableness and Conscientiousness, are 
represented by six facets, totalizing a group of 30. The NEO-FFI-R version usually 
used in Brazil is the S form – answered by the own individual – constituted by 
60 affirmatives. This instrument is suitable for people over 18 years of age and 
the Brazilian version was developed by Flores-Mendonza(28). The authors of this 
inventory found a Cronbach’s Alpha value that varied between 0.75 and 0.82(29). 
Aluja, Garcia, Rossier & Garcia(30) found internal consistency value for this 
instrument that varied between 0.70 and 0.87.
c) Hospital Anxiety and Depression Scale (HADS)(31): is a 14 itens self-
evaluation scale to measure symptoms of anxiety (HADS-A) and depression 
(HADS-D), in two subscales, that score from 0 to 21. The total score can vary 
between 0 and 42. It was used the Portuguese translated version adapted to Brazil 
by Botega, Bio, Zomignani, Garcia Júnior and Pereira(32). The cut-off points 
adopted for both subscales followed the recommendations available on the original 
scale(31): scores above seven (cut-off point eight) indicate the presence of anxiety 
and depression symptoms (doubtful cases) and scores above 11 (eleven) indicate 
clinical populations (definite cases).
Researches chose the cut-off point eight for cancer patients studies and found 
relevant results(1,5,33,34).A meta-analysis examined HADS adequacy as a screening 
tool for psychiatric disorders in cancer patients, established by a structured clinical 
interview. The HADS-D (depression) presented values of 0.76 for sensitivity and 
0.66 for specificity, and the HADS-A (anxiety) 0.66 and 0.71 respectively35. In the 
study of Hartung et al.3, involving cancer patients, the HADS-D presented internal 
consistency (Cronbach’s Alpha) of 0.85. Schellekens et al.(36) found good internal 
consistency values in lung cancer patients: HADS-A 0.88 and HADS-D 0.86.
2.4. Procedures
2.4.1. Data Collect
The research project corresponding to this study was submitted and approved 
by a Ethical Research Committee, recognized by the National Health Council 
(CNS) under the number 63367316.0.0000.5336. After that, the hospital oncology 
department was contacted and patients were invited to participate in the study. Those 
participants who accepted, signed the Free and Informed Consent (TCLE) and 
answered, individually, the evaluation instruments suggested, in a single meeting, 
with an average duration of forty-five minutes.
The individuals participation was voluntary and confidentiality was assured 
regarding the identity of the participants. When it was necessary, the patients were 
referred to free Psychology services, offered by the community. The evaluation was 
performed by a psychologist and two trained Psychology undergraduate students. 
3. Data Analysis
The data description was made by absolute (n) and relative (%) frequencies for 
qualitative variables, and by average and standard deviation for quantitative variables. 
The student t-test was used to compare means of HADS considering the variables sex, 
previous psychiatric history, family psychiatric history and family cancer history.
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The Spearman correlations – according to data non-normal distribution, pointed 
by Kolmogorov-Smirnov test – was used to verify the relation between five 
personality factors (big five) and symptoms of anxiety and depression, and the 
relation between sociodemographic variables (age, time since diagnosis, education 
level) and symptomatologies.
After that, a Multiple Linear Regression analysis (enter method) was made to 
verify the predictive power of the variables and the personality factors that presented 
significant statist relation with the symptomatologies. The version 17 of SPSS 
software was used for all analyzes, considering a 5% level of significance.
4. Results
The sample was composed by 220 individuals, 138 (62.7%) women and 82 (37.3%) 
men. The age mean was 54.66 (SD=13.30) years and the education level mean was 
8.32 (SD=3.76) years of study. Besides that, 56.4% were married, 66.8% were not 
working at the moment of the study and 78.6% claimed they are religious. More 
information about sociodemographic and clinical data can be found in Table 1.
 Table 1. Sociodemographic and clinical data of the sample (N=220)
Variables N %
Sex WomenMen
138
82
62.7
37.3
Age (years) Mean (SD) 54.66 (13.30)
Education (years) Mean (SD) 8.32 (3.76)
Marital status
Married 
Single
Widowed
Divorced 
124
49
26
21
56.4
22.3
11.8
9.5
Occupational situation Inactive Active
147
53
66.8
24.1
Religion Yes No
173
47
78.6
21.4
Family cancer history YesNo
152
68
70.0
30.0
Previous psychiatric history YesNo
46
174
21.0
79.0
Psychiatric medication YesNo
48
172
21.8
78.2
Medication category
Antidepressant 
Anxiolytic
Mood stabilizer
41
05
02
18.6
2.2
0.9
Family psychiatric history YesNo
55
165
25.0
75.0
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Variables N %
Time since diagnosis (months)
Average (SD)
0 to 12 
13 to 36
37 to 60 
> 60
36.21 (39.8)
78
76
30
33
35.9
35.0
13.8
15.0
Treatment
Chemotherapy
Surgery 
Radiotherapy
 158
 158
 91
71.8
71.8
71.4
Type of cancer
Mastology
Urology
Lung
Low Digestive
High Digestive
Hematology
Gynecology
Skin
Head and neck
Neurology (CNS)
Orthopedic/Traumatology
61
37
37
23
15
13
10
09
07
04
04
27.7
16.8
16.8
10.5
6.8
5.9
4.5
4.1
3.2
1.8
1.8
Source: Research data (2017).
The HADS results indicated that 47 patients (21.4%) scored above the established 
cut-off point for depression and 77 (35%) above the cut-off point 7, considered for 
subclinical cases, and only 23 (10.5%) above cut-off point 10, considered for clinical 
cases. Concerning anxiety, 77 (35%) participants scored above cut-off point 07 
(subclinical population) and 37 (16.8%) above cut-off point 10 (clinical population). 
The mean score for HADS-A was 6.50 (SD=4.29) and HADS-D was 4.63 (SD=3.92). 
It is important to highlight that 48 (21.8%) participants were allegedly undergoing 
psychiatric treatment, and 41 of these (18.6%) declared to take antidepressant. 
The scoring means of each personality factor were: neuroticism 23.06 (SD=7.21); 
extraversion 29.77 (SD=6.97); openness to experience 29.55 (SD=6.60); agreeableness 
34.19 (SD=5.88) and conscientiousness 37.35 (SD=5.49). The correlation results 
between symptoms of anxiety and depression, some sociodemographic variables and 
personality factors are presented in Table 2. 
The symptoms of depression presented a difference between gender [t(205)=-
2.81, p=0.005], indicating that women had higher mean values (M=5.16, SD=4.21) 
than men (M=3.74, SD=3.20). Depressive symptoms were also significantly different 
between the participants with and without previous psychiatric history [t(55)=-3.16, 
p=0.003]: participants with this history had a higher mean (M=6.63, SD=5,13) than 
those who did not report this information (M=4.10, SD=3.35).
Symptoms of anxiety diverged only between patients with and without previous 
psychiatric history [t(61)=-3.48, p=0.001]. The mean score of the patients with this 
history was higher (M=8.65, SD=4.91) than the average of patients without the history 
(M=5.93, SD=3.93). The variables family psychiatric history and family cancer 
history did not indicate difference between means regarding both symptomatologies.
The Multiple Linear Regression results are:
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– Anxiety: the presented model explained 37.2% of the variance, and the personality 
factor neuroticism was the only predictor of this symptomatology. The other variables 
(conscientiousness, agreeableness and previous psychiatric history) didn’t show predictive 
value, despite previous significant statistical association with symptoms of anxiety
– Depression: the model presented explained 30.4% of the variance. The presence 
of previous psychiatric history and the personality factors neuroticism and extraversion 
were shown as predictors of these symptoms. The other variables (agreeableness, 
conscientiousness, openness to experience and gender) did not present predictive 
value, even indicating statistically significant relation with symptoms of depression.
Table 3 presents the linear regression analysis detailed results, considering p≤.05.
Table 3. Multiple Linear Regression analysis 
Variables B SE β t IC 95% R R2a F p
 Depression
Previous 
psychiatric 
history
1.350 .575 .140 2.346 .216 – 2.484
Neuroticism .181 .034 .333 5.254 .113 – .248
Extraversion -.123 .037 -.218 -3.328 -.195 – -.050
Constant 6.371 2.448 2.602 1.545 – 11.197 .571 .304 14.688 <.001
 Anxiety
Neuroticism .332 .035 .558 9.351 .262 – .402
Constant 1.507 2.387 .631 -3.198 – 6.212 .620 .372 33.491 <.001
5. Discussion
The main goal of this study was to evaluate the presence of symptoms of depression 
and anxiety in cancer outpatients. The results indicate that a significant part of the 
sample shows both symptomatologies. Studies suggest that it is common to find 
Table 2. Spearman correlation analysis 
Variable Depression Anxiety
Personality factors
Neuroticism
Extraversion
Agreeableness
Openness to experience
Conscientiousness
r = .43**
r = -.33**
r = -.15*
r = -.18**
r = -.24**
r = .59**
r = -.06
r = -.19**
r = .03
r = -.19**
Sociodemographic variables
Age
Education level
Diagnostic time
r = .02
r = -.03
r = -.09
r = -.12
r = .08
r = -.11
Note: r= correlation coefficient; * p≤.05; ** p≤.01.
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these symptoms in cancer patients, because of the diagnostic impact and treatment 
consequences. Therefore, these findings agree with previous research(3, 5-7,12).
It is possible to perceive that the proportion of patients with symptoms of anxiety 
is bigger than that with depressive symptoms. Anxiety can be considered a patient 
adaptive answer to treatment adherence process or cancer screening.(37). In this way, 
it can be, somehow, expected, considering the person current situation. However, in 
some patients, anxiety can persist in a high and uncomfortable level(12,38). 
The diagnostic time and HADS-A can help to explain this result. The majority 
of the sample has a maximum of three years of disease diagnostic, which can result 
in higher degree of uncertainty about treatment and future32. On the other hand, 
even those with more time since diagnosis or those called survivors – who attended 
the outpatient clinic only for routine annual check-up, may still experience anxiety. 
They may feel anxiety focuses on the fear of recurrence, which is common in 
survivors, possibly lasting for many years post-treatment(39). Other potential 
sources of concern for these population, that may cause feelings of anxiety, are: 
worries about recovery from treatment in long term and worry about the impact of 
cancer on family, emotional and/or financial(40).
Beyond that, when answering the HADS scale, patients were asked to take last 
week into consideration – before data collect. Thus, it is believed that the week 
before medical appointment can increase patient’s anxiety, because he or she will 
possibly get updates about treatment, exams results or prognostic information.
The second objective of this research was to investigate the association 
between symptoms of depression and anxiety and sociodemographic variables and 
to verify if these variables have predictive value. The results pointed that previous 
psychiatric history is a predictor of depressive symptoms. The presence of previous 
psychiatric disorders can increase risk of comorbidity, like other mental disorder, 
for example, or even exacerbate the emotional symptoms. The symptoms relapse 
also can occur, especially if they were not properly treated(41-43).
The third and last goal of this study was to investigate the relation between 
symptoms of depression and anxiety and personality factors, and to verify the 
predictive value of these factors. According to the results neuroticism and 
extraversion are predictors of depressive symptoms and only neuroticism is 
a predictor of symptoms of anxiety. The result about the predictive value of 
neuroticism fits with other studies results(21,32,44,45). In a general manner, neuroticism 
is connected with negative life feelings, pessimist relationships and self depreciate 
thoughts, which make easier the emergence of feelings of sadness and ill-being(46).
People with higher levels of neuroticism, frequently evaluate small uncomfortable 
stimulus as having a higher potential of negative impact, and these threat perceptions 
can develop affective and cognitive depressive symptoms(47). Many times, these 
individuals present more demanding and unrealistic expectations about themselves, 
which can increase anxiety levels, impairing the coping of stress situations(48,49). One 
of the explanatory hypotheses is that patients symptoms of anxiety, in this study, may 
have been triggered by this process, which implies both neuroticism influence and 
coping of adverse situations, like cancer disease, for example.
Another predictor factor of depression symptoms is extraversion that, in this 
research, decrease the risk of symptoms. These results corroborate other studies found 
in the literature(50-53). A recent study, developed with brain tumor patients, also found a 
high correlation between depressive symptoms and low levels of extraversion(54). The 
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extroversion personality factor is, in fact, linked to expansion behaviors, social stimulation, 
more optimistic relationships, and to a more assertive attitude towards people(42,55). These 
characteristics have already pointed an inverse and significant association with a lower 
ability to tolerate frustrations, emotional instability, depressed mood, guilt, fatigue and loss 
of interest(56), features and symptoms found in individuals with high levels of neuroticism.
It is possible to conclude that the prevalence of anxiety and depression 
symptoms in cancer outpatients is high, and these symptomatologies are associated 
with some sociodemographic variables and personality factors, like neuroticism 
and extraversion. Therefore, these variables can be deemed risk factors for the 
development of these symptoms. The association between some personality factors 
with anxiety and depression, as reported in this article, seems to be already established 
in the literature. However, most of the mentioned studies were developed with non-
clinical populations, unlike the present study. For that matter, it is believed that this 
association should also be considered mostly in cases of individuals with cancer 
diagnostic, in face of the damage caused by symptoms of anxiety and depression to 
the treatment and rehabilitation of cancer patients. 
It is important that health professionals who treat and follow-up this population 
design strategies to collect this information, in order to help patients manage 
to treatment the best way possible. Finally, some limitations of the study need to 
be mentioned. The sample evaluated is originated from only one health service 
establishments, which can difficult the results generalization. Besides that, the 
patient’s cancer staging and the outcome of relative’s disease of those participants 
with family cancer history were not assessed, and these variables could help 
grounding the prevalence of symptoms of anxiety and depression in this sample. 
Future research should be developed with different samples, coming from different 
health care settings, and including the evaluation of these clinical aspects of disease, 
which can also influence the symptoms presence and/or magnitude.
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